A Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps
A legfontosabb adatok
- Ki végzi
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 30 fő, tervezett
- Kezdés
- 2025. aug. 18.
- Tervezett befejezés
- 2026. jún.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- HTMC0658
- A regiszteradat frissítve
- 2025. szeptember 19.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with long-lasting sinus inflammation without nasal polyps (CRSsNP). Their symptoms continue despite mometasone furoate nasal spray.
- Életkor
- 18 to 75 years
- Nem
- All sexes
- A betegség stádiuma
- Chronic rhinosinusitis without nasal polyps for more than 12 weeks, in both sides of the nose and sinuses on endoscopy or CT scan. Each side must have at least one sinus scoring ≥ 1 point on the Lund-MacKay scale. Nasal Congestion Score ≥ 2 points, Composite Symptom Score ≥ 5 points, SNOT-22 score ≥ 20 points. BMI of at least 18.5. Asthma or COPD must have been stable for 3 months.
- Korábbi kezelés
- People must have used a stable daily dose of mometasone furoate nasal spray (MFNS) for at least 4 weeks. People cannot join if they had nasal surgery within 4 weeks, or need steroid pills or injections as ongoing treatment. Strong CYP3A4 or CYP2D6 inhibitors or inducers are not allowed within 14 days. Drugs such as tumor necrosis factor-α antagonists are not allowed within 4 weeks.
A részvétel fő kizáró okai
- Nasal polyps now or in the past
- Cystic fibrosis, primary ciliary dyskinesia, fungal or tooth-related sinus infection, or nasal tumor
- Gum disease (gingivitis/periodontitis) or thickened skin on palms and soles
- Positive test for hepatitis B, hepatitis C, HIV or syphilis
- Current smokers, and pregnant or breastfeeding women
A regiszter feltételei, szó szerint
Mind a 32 feltétel megnézéseKevesebb
Ki vehet részt
- Subjects aged between 18 and 75 years, inclusive, of either sex
- Body Mass Index (BMI) calculated as weight in kilograms divided by the square of height in meters (kg/m²), with a BMI of at least 18.5
- Subjects must meet the diagnostic criteria for chronic rhinosinusitis as defined in the "Chinese Chronic Rhinosinusitis Diagnosis and Treatment Guidelines (2024)," with a disease duration exceeding 12 weeks
- During the screening period, nasal endoscopy must reveal bilateral pathological changes in the nasal mucosa, such as edema and purulent discharge, or a CT scan must show bilateral sinus involvement
- During the screening period, a CT scan must demonstrate bilateral sinus involvement, with at least one sinus on each side scoring ≥ 1 point on the Lund-MacKay (LMK) scale
- During the screening period, the Nasal Congestion Score (NCS) must be ≥ 2 points
- During the screening period, the Composite Symptom Score (CSS) for nasal congestion, rhinorrhea, and facial pain/pressure must be ≥ 5 points
- During the screening period, the Sino-Nasal Outcome Test-22 (SNOT-22) total score must be ≥ 20 points
- Subjects must have been on a stable daily dose of mometasone furoate nasal spray (MFNS) for at least 4 weeks prior to enrollment
- Subjects with asthma or chronic obstructive pulmonary disease (COPD) must have had stable conditions without exacerbations in the 3 months prior to screening (e.g., no emergency room visits, hospitalizations, or systemic corticosteroid use). The use of inhaled corticosteroids must have been at a stable dose, with continuous use for at least 3 months prior to screening, and planned continuation throughout the study period
- Subjects must fully understand the purpose, nature, methodology, and potential adverse events of the trial, voluntarily participate in the trial, and provide written informed consent, or have an authorized legal representative provide informed consent
Ki nem vehet részt
- Requirement for systemic corticosteroids as maintenance therapy during the screening period
- Undergone nasal surgery within 4 weeks prior to screening, or scheduled for sinus surgery during the study period
- Presence of a disease or comorbidity that would interfere with the assessment of the primary efficacy endpoints (e.g., subjects with seasonal allergic rhinitis whose symptoms coincide with the study treatment period; subjects with moderate to severe atopic dermatitis requiring treatment with potent topical corticosteroids, topical calcineurin inhibitors, or biologics; subjects with acute upper respiratory tract infection that, in the investigator's judgment, would affect nasal symptom scoring)
- Presence of an acute infection requiring antibiotic treatment within 4 weeks prior to screening
- Receipt of drugs that may cause skin hyperkeratosis (e.g., tumor necrosis factor-α antagonists) within 4 weeks prior to screening
- Patients who have used strong CYP3A4 or CYP2D6 inhibitors or inducers within 14 days prior to the first administration of the investigational medicinal product
- Subjects who have participated in other drug or medical device trials within 3 months prior to the start of this trial or are currently enrolled in another clinical trial
- Presence of nasal polyps confirmed by nasal endoscopy during the screening period, or a history of nasal polyps
- Inflammatory or autoimmune diseases requiring systemic biologic therapy or immunosuppressive agents (including but not limited to immunodeficiency diseases)
- Known allergy or intolerance to any component of the investigational medicinal product or background therapy
- Subjects with a past or current diagnosis of periodontitis or palmoplantar keratoderma due to functional deficiency of dipeptidyl peptidase 1 (DPP1), or the presence of the following at screening:a. Subjects with current signs of gingivitis/periodontitis.b. Subjects with a history of palmoplantar keratoderma or erythema
- Subjects with positive test results for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, and/or syphilis serology during the screening period
- Subjects with elevated liver function test results during the screening period and currently requiring treatment for liver disease. Elevated liver function tests are defined as: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.0 × upper limit of normal (ULN), or total bilirubin (TBIL) > 1.5 × ULN
- Diagnosis of cystic fibrosis (CF) or primary ciliary dyskinesia
- Presence of significant craniofacial structural abnormalities or severe nasal septal deviation
- Radiological suspicion or confirmed diagnosis of invasive fungal rhinosinusitis, odontogenic sinusitis, osteoma, or nasal tumor
- Current smokers (defined as adults who have smoked at least 100 cigarettes in their lifetime and are currently smoking) or those who cannot abstain from smoking during the trial
- Male subjects who plan to donate sperm or have a fathering plan from the start of dosing until 90 days after the last dose and are unwilling to use effective non-pharmacological contraceptive measures
- Female subjects who plan to donate oocytes or have a pregnancy plan from the start of dosing until 30 days after the last dose and are unwilling to use effective non-pharmacological contraceptive measures
- Pregnant or breastfeeding women
- Subjects whom the investigator deems unsuitable for participation in this study for any reason
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Kína.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this clinical trial is to assess the efficacy and safety of HTMC0658 tablets in treating subjects with chronic rhinosinusitis without nasal polyps (CRSsNP).
A vizsgálat csoportja
- HTMC0658A vizsgált kezelés
Participants will receive HTMC0658 tablet, orally, QD for 12 weeks along with mometasone furoate nasal spray (MFNS) by nasal route as background therapy at a stable dose according to the Investigator's discretion and local guidance.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase IIa Clinical Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- Kérdések a feltételekről
- Forrás: NCT07174115: ki vehet részt
- A regiszteradat frissítve
- 2025. szeptember 19.